Correlation of Xanthelasma With Atherosclerosis, Hepatic Fat and Fibrosis
NCT ID: NCT05945030
Last Updated: 2023-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2023-07-01
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives:
Primary
1. To correlate xanthelasma and its severity to pulse wave velocity and atherosclerosis as see in carotid doppler.
Secondary
2. To correlate xanthelasma to liver fat and fibrosis.
Methodology:
T2DM patient will be recruited from endocrine OPD
1. Clinical History and Examination:
a. General Physical Examination: Height, weight, waist circumference, hip circumference, BMI, Blood Pressure, Hand grip. Xanthelasma.
2. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits
1. Fasting blood Glucose
2. Haemoglobin A1C: The estimation of average blood sugar level over a period of two to three months will be analysed with the patient's blood sample for haemoglobin A1C based on turbidimetric inhibition immunoassay method (using COBAS 6000 analyser)
3. Lipid Profile: Fasting samples shall be analysed for lipid profile. Levels of total cholesterol (TC), serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-c) will be estimated using commercial kits (Randox Laboratory, USA). Value of low-density lipoprotein cholesterol (LDL-c) will be calculated according to Friedewald's equation.
4. Liver Function Tests: Fasting samples shall be analysed for liver function test. Levels of alkaline phosphate, Aspartate aminotransferase, Alanine aminotransferase and Gamma-glutamyl transferase will be estimated by using commercial kits (based on kinetic method).
3. Assessment of sub-clinical atherosclerosis: Pulse wave velocity and carotid Doppler will be done
1. Pulse wave velocity: Arterial stiffness indices will be analyzed by measuring carotid femoral pulse wave velocity.
2. Carotid Doppler: (based on kinetic method)
3. FibroScan Estimation: It is a medical diagnostic tool. Liver stiffness (LSM in kPa) and controlled attenuation parameter (CAP in dB/m) measurements will be done by transient elastography (FibroScan® 430 Touch, Echosens, FR) in order to quantify severity of liver fibrosis (LSM 7-10 kPa for F1, 10.1-13 for F2 and \>13kPa for F≥3
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relation Between Carotid Atheroscerosis With DM &Fatty Liver
NCT05532553
Carotid Atherosclerosis and Vascular Events in People With Diabetes
NCT02929355
Comparison of Micro- and Macrovascular Disease(s) in People With T2D, Who Have Moderate to Severe Acanthosis Nigricans vs. Those Who do Not Have Acanthosis Nigricans
NCT06386939
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
NCT05317845
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
NCT05597709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Xanthelasma palpebrarum (XP) are yellow plaques that occur most commonly near the inner canthus of the eyelid and are often associated with atherosclerosis, dyslipidaemia, and coronary artery disease. About 50% of patients who develop xanthelasma have lipid disorder. It is commonly seen in patients with: Type II hyperlipidaemia that includes type IIa, also known as familial hypercholesterolemia, and type IIb, which is commonly referred to as familial combined hyperlipidaemia Type IV hyperlipidaemia, which is also known as familial hypertriglyceridemia: - Diabetes mellitus; Hypothyroidism; Those with low levels of HDL; Fatty diet; Excess alcohol intake; Weight gain.
A significant number of cases of xanthelasma palpebrarum are combined with smoking, central obesity, hypertension, diabetes mellitus, and dyslipidemia which are the major risk factors for CAD. Efforts should be made to rule out the same in high-risk xanthelasma subjects.
Patients with type 2 diabetes mellitus (T2DM) have a high cardiovascular risk even at young age. There is a need to assess this increased risk and identify atherosclerosis early so that appropriate measures for risk reduction can be taken. The Investigators aimed to study carotid-femoral pulse wave velocity (Cf-PWV), a non-invasive indicator of atherosclerosis, in patients with diabetes below 50 years of age and its correlation with markers of obesity and other cardiovascular risk factors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With Xanthelasma
T2DM with Xanthelasma
Clinical Examination
T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
Without Xanthelasma
T2DM without Xanthelasma
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical Examination
T2DM patient visiting Fortis CDOC will undergo clinical examination to determine the grade of Xanthelasma.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 25 to 60 years
3. BMI \>25 kg/m² to \>40 kg/m²
4. Gender- Both (Male \& Female)
5. Mild, moderate and severe Xanthelasma (Photograph)
Exclusion Criteria
2. Severe end organ damage or chronic diseases: renal/hepatic failure, any malignancy, major systemic illness etc.
25 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Diabetes Obesity and Cholesterol Foundation
OTHER
Diabetes Foundation, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Anoop Misra
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anoop Misra, MD
Role: PRINCIPAL_INVESTIGATOR
Fortis CDOC Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fortis CDOC Hospital
Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-24/01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.